This inventor holds 5 USPTO granted patents and 1 published patent application. Top assignee: Novo Nordisk A/s. Active years: 1992-2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Bagsvaerd, DK (1992 - 1993)
- Soborg, DK (2000)
Company Filing History:
Years Active: 1992-2000
Title: Carsten Enggaard Stidsen: Innovator in Somatostatin Research
Introduction
Carsten Enggaard Stidsen is a notable inventor based in Soborg, Denmark. He has made significant contributions to the field of medical research, particularly in the development of treatments for various ocular diseases. With a total of 5 patents to his name, Stidsen's work focuses on the use of somatostatin agonists and antagonists.
Latest Patents
Stidsen's latest patents include innovative methods for utilizing somatostatin receptor ligands for therapeutic purposes. One of his key inventions involves the use of a somatostatin receptor ligand of nonpeptide origin, which has a high affinity for the somatostatin receptor protein designated SSTR4. This invention aims to prepare a medicament for treating diseases associated with adverse conditions in the retina and iris-ciliary body of mammals. Conditions such as high intraocular pressure (IOP) and deep ocular infections can be addressed through this invention, which targets diseases like glaucoma, stromal keratitis, iritis, retinitis, cataract, and conjunctivitis. Another significant patent focuses on constrained somatostatin agonists and antagonists, which are compounds designed to treat medical disorders related to binding to human somatostatin receptor subtypes.
Career Highlights
Carsten Enggaard Stidsen is currently associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk has allowed him to further his research and contribute to advancements in medical treatments.
Collaborations
Stidsen has collaborated with notable colleagues, including Michael Ankersen and Florenzio Zaragoza Dorwald. These collaborations have enhanced the scope and impact of his research in the field of somatostatin-related therapies.
Conclusion
Carsten Enggaard Stidsen's innovative work in somatostatin research has the potential to significantly improve treatment options for various ocular diseases. His contributions to the field are marked by a commitment to advancing medical science through his patents and collaborations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile